3D Whole-body skin imaging for automated melanoma detection.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
May 2023
Historique:
received: 21 09 2022
accepted: 16 01 2023
medline: 17 4 2023
pubmed: 29 1 2023
entrez: 28 1 2023
Statut: ppublish

Résumé

Existing artificial intelligence for melanoma detection has relied on analysing images of lesions of clinical interest, which may lead to missed melanomas. Tools analysing the entire skin surface are lacking. To determine if melanoma can be distinguished from other skin lesions using data from automated analysis of 3D-images. Single-centre, retrospective, observational convenience sample of patients diagnosed with melanoma at a tertiary care cancer hospital. Eligible participants were those with a whole-body 3D-image captured within 90 days prior to the diagnostic skin biopsy. 3D-images were obtained as standard of care using VECTRA WB360 Whole Body 3-dimensional Imaging System (Canfield Scientific). Automated data from image processing (i.e. lesion size, colour, border) for all eligible participants were exported from VECTRA DermaGraphix research software for analysis. The main outcome was the area under the receiver operating characteristic curve (AUC). A total of 35 patients contributed 23,538 automatically identified skin lesions >2 mm in largest diameter (102-3021 lesions per participant). All were White patients and 23 (66%) were males. The median (range) age was 64 years (26-89). There were 49 lesions of melanoma and 22,489 lesions that were not melanoma. The AUC for the prediction model was 0.94 (95% CI: 0.92-0.96). Considering all lesions in a patient-level analysis, 14 (28%) melanoma lesions had the highest predicted score or were in the 99th percentile among all lesions for an individual patient. In this proof-of-concept pilot study, we demonstrated that automated analysis of whole-body 3D-images using simple image processing techniques can discriminate melanoma from other skin lesions with high accuracy. Further studies with larger, higher quality, and more representative 3D-imaging datasets would be needed to improve and validate these results.

Sections du résumé

BACKGROUND BACKGROUND
Existing artificial intelligence for melanoma detection has relied on analysing images of lesions of clinical interest, which may lead to missed melanomas. Tools analysing the entire skin surface are lacking.
OBJECTIVES OBJECTIVE
To determine if melanoma can be distinguished from other skin lesions using data from automated analysis of 3D-images.
METHODS METHODS
Single-centre, retrospective, observational convenience sample of patients diagnosed with melanoma at a tertiary care cancer hospital. Eligible participants were those with a whole-body 3D-image captured within 90 days prior to the diagnostic skin biopsy. 3D-images were obtained as standard of care using VECTRA WB360 Whole Body 3-dimensional Imaging System (Canfield Scientific). Automated data from image processing (i.e. lesion size, colour, border) for all eligible participants were exported from VECTRA DermaGraphix research software for analysis. The main outcome was the area under the receiver operating characteristic curve (AUC).
RESULTS RESULTS
A total of 35 patients contributed 23,538 automatically identified skin lesions >2 mm in largest diameter (102-3021 lesions per participant). All were White patients and 23 (66%) were males. The median (range) age was 64 years (26-89). There were 49 lesions of melanoma and 22,489 lesions that were not melanoma. The AUC for the prediction model was 0.94 (95% CI: 0.92-0.96). Considering all lesions in a patient-level analysis, 14 (28%) melanoma lesions had the highest predicted score or were in the 99th percentile among all lesions for an individual patient.
CONCLUSIONS CONCLUSIONS
In this proof-of-concept pilot study, we demonstrated that automated analysis of whole-body 3D-images using simple image processing techniques can discriminate melanoma from other skin lesions with high accuracy. Further studies with larger, higher quality, and more representative 3D-imaging datasets would be needed to improve and validate these results.

Identifiants

pubmed: 36708077
doi: 10.1111/jdv.18924
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

945-950

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Informations de copyright

© 2023 European Academy of Dermatology and Venereology.

Références

Fried L, Tan A, Bajaj S, Liebman TN, Polsky D, Stein JA. Technological advances for the detection of melanoma: advances in diagnostic techniques. J Am Acad Dermatol. 2020;83(4):983-92. https://doi.org/10.1016/j.jaad.2020.03.121
Fried L, Tan A, Bajaj S, Liebman TN, Polsky D, Stein JA. Technological advances for the detection of melanoma: advances in molecular techniques. J Am Acad Dermatol. 2020;83(4):996-1004. https://doi.org/10.1016/j.jaad.2020.03.122
Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, et al. Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. Eur J Cancer. 2021;156:202-16. https://doi.org/10.1016/j.ejca.2021.06.049
Malvehy J, Hauschild A, Curiel-Lewandrowski C, Mohr P, Hofmann-Wellenhof R, Motley R, et al. Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. Br J Dermatol. 2014;171(5):1099-107. https://doi.org/10.1111/bjd.13121
Brouha B, Ferris LK, Skelsey MK, Peck G, Moy R, Yao Z, et al. Real-world utility of a non-invasive gene expression test to rule out primary cutaneous melanoma: a large US registry study. J Drugs Dermatol. 2020;19(3):257-62.
VECTRA 3D Whole Body 3D Imaging. Canfield. https://www.canfieldsci.com/imaging-systems/vectra-wb360-imaging-system/. Accessed 10 August 2022.
Betz-Stablein B, D'Alessandro B, Koh U, Plasmeijer E, Janda M, Menzies SW, et al. Reproducible Naevus counts using 3D Total body photography and convolutional neural networks. Dermatology. 2022;238(1):4-11. https://doi.org/10.1159/000517218
Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80(1):27-38. https://doi.org/10.2307/2336755
Abbasi NR, Shaw HM, Rigel DS, Friedman RJ, McCarthy WH, Osman I, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA. 2004;292(22):2771-6. https://doi.org/10.1001/jama.292.22.2771
Welch HG, Kramer BS, Black WC. Epidemiologic signatures in cancer. N Engl J Med. 2019;381(14):1378-86. https://doi.org/10.1056/NEJMsr1905447
Kurtansky NR, Dusza SW, Halpern AC, Hartman RI, Geller AC, Marghoob AA, et al. An epidemiologic analysis of melanoma Overdiagnosis in the United States, 1975-2017. J Invest Dermatol. 2022;142(7):1804-11.e6. https://doi.org/10.1016/j.jid.2021.12.003

Auteurs

M A Marchetti (MA)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Z H Nazir (ZH)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.

J K Nanda (JK)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Department of Dermatology, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA.

S W Dusza (SW)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

B M D'Alessandro (BM)

Canfield Scientific, Inc., Parsippany, New Jersey, USA.

J DeFazio (J)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

A C Halpern (AC)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

V M Rotemberg (VM)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

A A Marghoob (AA)

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH